** Shares of Cann Group Ltd CAN.AX fall as much as 9.8% to
a record low of A$0.185
** Stock eyes worst day since Oct. 25, 2022, if losses hold
** Medicinal cannabis maker announces phase 3 clinical trial
results for its Satipharm CBD capsule used to treat sleep
disturbances
** Says preliminary view of analysis for primary end-points
have not shown a statistically superior response
** Co expects trial results to delay submission of the
registration application to the Therapeutic Goods Administration
(TGA)
** Stock fell 29.3% in 2022
(Reporting by Nausheen Thusoo in Bengaluru)
((Nausheen.Thusoo@thomsonreuters.com;))